MD Medical Footer

MD The value proposition for innovation header

IJ Navbar

<table>
<tbody>
<tr>
<td>
<img src="https://cdn.buttercms.com/UyB6xpj4RU2AtZjVAsZ4" alt="checkmark">Assist in determining whether your device is valid for this model
</td>
<td>
<img src="https://cdn.buttercms.com/UyB6xpj4RU2AtZjVAsZ4" alt="checkmark">Articulate &amp; quantify benefits, value proposition &amp; outcomes
</td>
<td>
<img src="https://cdn.buttercms.com/UyB6xpj4RU2AtZjVAsZ4" alt="checkmark">Constant reevaluation of the process, data and outcomes
</td>
</tr>
</tbody>
</table>

<table>
<tbody>
<tr>
<td>
<img src="https://cdn.buttercms.com/UyB6xpj4RU2AtZjVAsZ4" alt="checkmark">Access to the data to validate the outcome or value
</td>
<td>
<img src="https://cdn.buttercms.com/UyB6xpj4RU2AtZjVAsZ4" alt="checkmark">Transparent access shared with the key players in the value chain
</td>
<td>
<img src="https://cdn.buttercms.com/UyB6xpj4RU2AtZjVAsZ4" alt="checkmark">Inight into the impact of government pricing, government programs and rebates
</td>
</tr>
</tbody>
</table>

Access to the data to validate the outcome or value

Transparent access shared with the key players in the value chain

Insight into the impact of government pricing, government programs and rebates

You&rsquo;re navigating a challenging landscape
As governments and insurance companies tighten their belts, hospitals are forced to operate with leaner budgets, and private facilities receive fewer reimbursements. As the manufacturer, you will require a more significant stake in the outcomes to justify the high costs of your products.

The regulatory tango
Regulatory hurdles pose challenges and also hinder the adoption of value-based contracts. Organizations are collaborating with federal agencies to reevaluate certain regulations, particularly the anti-kickback statute and Stark Law. In Europe, while certain countries may impose price controls or regulatory constraints on the pricing strategies of medical device companies, adopting value-based procurement is a reality. This shift is supported by the EU directive on public procurement (like 2014/24), where evaluations are conducted based on two critical factors: the total cost of ownership (TCO) and the price-quality ratio.

What gets managed, gets measured
Successful pricing strategies for medical devices hinge on accurately gauging your customers&rsquo; willingness to pay. Value has multiple dimensions and is challenging to manage and quantify (economic, clinical, operational and emotional), but to thrive in this landscape, you must align your pricing strategies accurately. Your success depends not only on strategy but also on execution. Effectively managing pricing models is crucial for optimizing Gross-to-Net (GtN) and ensuring overall business success. However, the stakes are even higher when dealing with value-based models with complex terms and conditions.

The fragmented truth trap
Relying on multiple sources of &ldquo;truth&rdquo; to navigate these complexities often leads to challenges in maintaining transparency and accuracy, from price definition to execution, including value chain incentives like rebates, for the final value proposition. One end-to-end solution providing a single truth source is critical to gaining model visibility in your GtN. How can you reflect this in your GtN without the ability to view pricing holistically?